Rho-Signaling Pathways in Chronic Myelogenous Leukemia

E-ISSN： 2212-4063|8|4|261-267

ISSN： 1871-529X

Source： Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol.8, Iss.4, 2008-12, pp. : 261-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel therapies for chronic myelogenous leukemia

By Jahagirdar B.N. Miller J.S. Shet A. Verfaillie C.M.

Experimental Hematology, Vol. 29, Iss. 5, 2001-05 ,pp. : 543-556

Elsevier

Access to resources Recommend Favorite

Hematology clinic: chronic myelogenous leukemia

By Weber Alissa A. Talpaz Moshe

Hematology, Vol. 18, Iss. 6, 2013-11 ,pp. : 371-372

Maney Publishing

Access to resources Recommend Favorite

Allogeneic transplantation for chronic myelogenous leukemia

By McGlave Philip

Hematology, Vol. 10, Iss. 1, 2005-09 ,pp. : 15-18

Maney Publishing

Access to resources Recommend Favorite

Posttransplantation epstein-barr viral meningitis in a patient with chronic myelogenous leukemia

By Kanamori Heiwa Fujisawa Shin Yamaji Satoshi Tanaka Masatsugu Tomita Naoto Fujimaki Katsumichi Ishigatsubo Yoshiaki

International Journal of Hematology, Vol. 74, Iss. 4, 2001-12 ,pp. : 473-474

Springer Publishing Company

Access to resources Recommend Favorite

Anagrelide for Treatment of Patients with Chronic Myelogenous Leukemia and a High Platelet Count

By Trapp O.M. Beykirch M.K. Beutler P.E.E.

Blood Cells, Molecules, and Diseases, Vol. 24, Iss. 1, 1998-03 ,pp. : 9-13

Academic Press

Access to resources Recommend Favorite